Alexion, AstraZeneca Rare Disease
(https://alexion.com) 📸 Data Snapshot: May 26, 2026Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.
The site avoids common trust theatre traps like unverified testimonials. While the review_count is 0, the proof_links_count is 1 on every major page, leading to a robust ‘References’ section on the ‘Living with Rare’ page that cites the Orphanet Journal of Rare Diseases and the EveryLife Foundation. The presence of Veeva IDs (e.g., Veeva ID: GL/ALL/0039) serves as a high-authority signal of regulatory compliance in the pharmaceutical industry.
The proof density is high for a corporate pharma site, particularly regarding disease awareness. The site provides 8 specific external references to validate its claims about the rare disease landscape. The ratio of vague assertions like ‘pioneering new possibilities’ is balanced by the ‘Rare Disease by the Numbers’ section which uses five distinct data points to ground the narrative.
Trust & Proof is read by weighing trust language against real verification. Below is the page-by-page tally of review mentions and external proof links, then the schema markup that may (or may not) declare verifiable ratings and identity proof.
🛡️ Trust Signals — reviews, proof links, trust-theatre check
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 1 |
| /news-centre-resources/ | 0 | 1 |
| /living-in-rare/ | 0 | 1 |
| /innovation/ | 0 | 1 |
🔗 Identity & Technical Layer — schema JSON-LD: declared ratings, reviews & identity proof
Homepage schema
[
{
"@context": "https://schema.org",
"@type": "Organization",
"name": "Alexion",
"alternateName": "Alexion",
"url": "http://alexion.com/",
"logo": "",
"sameAs": [
"https://www.instagram.com/alexionpharmaus/",
"https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
"https://www.linkedin.com/company/alexion-pharmaceuticals/"
]
},
{
"@context": "https://schema.org",
"@type": "WebSite",
"name": "Alexion",
"url": "http://alexion.com/"
},
{
"@context": "https://schema.org",
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://alexion.com/"
}
]
},
{
"@context": "https://schema.org",
"@type": "ItemList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Pioneering new possibilities for the rare disease community",
"url": "http://alexion.com/sitecore/content/alexion_global/shared-content/homepage-carousel-slides/homepage-carousel-masthead-slides-pioneering-new-possibilities"
},
{
"@type": "ListItem",
"position": 2,
"name": "More than 400 Million People Live with a Rare Disease",
"url": "http://alexion.com/sitecore/content/alexion_global/shared-content/homepage-carousel-slides/homepage-carousel-masthead-slides-more-than-400-million-people"
},
{
"@type": "ListItem",
"position": 3,
"name": "Leading the Charge in Rare Disease Research",
"url": "http://alexion.com/sitecore/content/alexion_global/shared-content/homepage-carousel-slides/homepage-carousel-masthead-slides-leading-the-charge"
}
]
},
{
"@context": "https://schema.org",
"@type": "ItemList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Understanding treatment impact and addressing disparities in rare disease care",
"url": "http://alexion.com/news-centre-resources/articles/understanding-treatment-impact-and-addressing-disparities-in-rare-disease-care"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tina’s Big Trip",
"url": "http://alexion.com/news-centre-resources/articles/tinas-big-trip"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pioneering new possibilities for the rare disease community",
"url": "http://alexion.com/news-centre-resources/articles/pioneering-new-possibilities-for-the-rare-disease-community"
},
{
"@type": "ListItem",
"position": 4,
"name": "Shaping the future of R&D with real world insights into rare disease",
"url": "http://alexion.com/news-centre-resources/articles/shaping-the-future-of-rd-with-real-world-insights-into-rare-disease"
},
{
"@type": "ListItem",
"position": 5,
"name": "Genomic Innovation to Support Newborn Screening of Rare Diseases",
"url": "http://alexion.com/news-centre-resources/articles/newborn-screening"
},
{
"@type": "ListItem",
"position": 6,
"name": "Paving Regulatory Pathways in Rare Disease",
"url": "http://alexion.com/news-centre-resources/articles/paving-regulatory-pathways-in-rare-disease"
},
{
"@type": "ListItem",
"position": 7,
"name": "Advancing Rare Disease Research Through Patient-Centric Trial Design",
"url": "http://alexion.com/news-centre-resources/articles/patient-centric-clinical-trial"
},
{
"@type": "ListItem",
"position": 8,
"name": "Addressing the Unmet Needs of the Amyloidosis Community ",
"url": "http://alexion.com/news-centre-resources/articles/addressing-the-unmet-needs-of-the-amyloidosis-community"
},
{
"@type": "ListItem",
"position": 9,
"name": "Getting to know Nick France, an Alexion R&D Leading Voice",
"url": "http://alexion.com/news-centre-resources/articles/getting-to-know-nick-france"
},
{
"@type": "ListItem",
"position": 10,
"name": "Getting to know Chathuri Daluwatte, an Alexion R&D Leading Voice",
"url": "http://alexion.com/news-centre-resources/articles/getting-know-chathuri-daluwatte-alexion-rd-leading-voice"
},
{
"@type": "ListItem",
"position": 11,
"name": "Getting to know Seng Cheng, an Alexion R&D Leading Voice",
"url": "http://alexion.com/news-centre-resources/articles/getting-know-seng-cheng-alexion-rd-leading-voice"
},
{
"@type": "ListItem",
"position": 12,
"name": "Getting to know Sophia Zilber, Associate Director, Statistical Programming",
"url": "http://alexion.com/news-centre-resources/articles/getting-know-sophia-zilber-associate-director-statistical"
},
{
"@type": "ListItem",
"position": 13,
"name": "Getting to know Banu Sankaran, an Alexion R&D Leading Voice",
"url": "http://alexion.com/news-centre-resources/articles/getting-know-banu-sankaran-alexion-rd-leading-voice"
},
{
"@type": "ListItem",
"position": 14,
"name": "Driving health equity for the rare disease community",
"url": "http://alexion.com/news-centre-resources/articles/driving-health-equity-rare-disease-community"
},
{
"@type": "ListItem",
"position": 15,
"name": "Understanding & Overcoming the Challenges in Rare Disease Clinical Trials",
"url": "http://alexion.com/news-centre-resources/articles/understanding-overcoming-challenges-rare-disease-clinical-trials"
}
]
}
]
/news-centre-resources/
[
{
"@context": "https://schema.org",
"@type": "Organization",
"name": "Alexion",
"alternateName": "Alexion",
"url": "http://alexion.com/news-centre-resources",
"logo": "",
"sameAs": [
"https://www.instagram.com/alexionpharmaus/",
"https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
"https://www.linkedin.com/company/alexion-pharmaceuticals/"
]
},
{
"@context": "https://schema.org",
"@type": "WebSite",
"name": "Alexion",
"url": "http://alexion.com/news-centre-resources"
},
{
"@context": "https://schema.org",
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://alexion.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "News Centre Resources",
"item": "http://alexion.com/news-centre-resources"
}
]
}
]
/living-in-rare/
[
{
"@context": "https://schema.org",
"@type": "Organization",
"name": "Alexion",
"alternateName": "Alexion",
"url": "http://alexion.com/living-in-rare",
"logo": "",
"sameAs": [
"https://www.instagram.com/alexionpharmaus/",
"https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
"https://www.linkedin.com/company/alexion-pharmaceuticals/"
]
},
{
"@context": "https://schema.org",
"@type": "WebSite",
"name": "Alexion",
"url": "http://alexion.com/living-in-rare"
},
{
"@context": "https://schema.org",
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://alexion.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Living with Rare Disease",
"item": "http://alexion.com/living-in-rare"
}
]
}
]
/innovation/
[
{
"@context": "https://schema.org",
"@type": "Organization",
"name": "Alexion",
"alternateName": "Alexion",
"url": "http://alexion.com/innovation",
"logo": "",
"sameAs": [
"https://www.instagram.com/alexionpharmaus/",
"https://www.youtube.com/channel/UCbDpNIQcl0lsU3pmCOSJTrA",
"https://www.linkedin.com/company/alexion-pharmaceuticals/"
]
},
{
"@context": "https://schema.org",
"@type": "WebSite",
"name": "Alexion",
"url": "http://alexion.com/innovation"
},
{
"@context": "https://schema.org",
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "http://alexion.com/"
},
{
"@type": "ListItem",
"position": 2,
"name": "Innovation",
"item": "http://alexion.com/innovation"
}
]
},
{
"@context": "https://schema.org",
"@type": "ItemList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Data Science and AI",
"url": "http://alexion.com/innovation/data-science-and-ai"
},
{
"@type": "ListItem",
"position": 2,
"name": "Diagnostics",
"url": "http://alexion.com/innovation/diagnostics"
},
{
"@type": "ListItem",
"position": 3,
"name": "Genomics",
"url": "http://alexion.com/innovation/genomics"
}
]
}
]
This page presents a snapshot of public data from Alexion, AstraZeneca Rare Disease, captured on May 26, 2026, to show how machine logic reads Trust & Proof signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Alexion, AstraZeneca Rare Disease: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://alexion.com to view the most current version of its content and see directly what this company is about and what it offers.